Pliant Therapeutics Income Statement (2019-2026) | PLRX

Income Statement Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
1.79M1.61M2.00M1.25M4.99M1.48M1.97M1.33M0.25M
Operating items
Research & Development (Quarter)
19.22M21.05M18.75M20.88M26.34M24.61M25.11M29.27M33.00M32.34M33.18M37.15M45.62M47.75M38.79M43.44M32.20M17.94M15.59M13.58M
Selling, General & Administrative (Quarter)
5.47M7.67M7.85M8.58M8.30M8.82M14.25M14.15M14.57M15.35M13.85M15.25M15.02M14.26M14.53M15.50M13.39M10.33M7.99M8.19M
Operating Expenses (Quarter)
24.69M28.72M26.60M29.46M34.63M33.43M39.37M43.43M47.58M47.69M47.04M52.39M60.64M62.01M53.32M58.94M45.59M28.27M23.58M21.77M
Operating Income (Quarter)
-22.90M-27.11M-24.60M-28.21M-29.64M-31.95M-37.40M-42.09M-47.33M-47.69M-47.04M-52.39M-60.64M-62.01M-53.32M-58.94M-45.59M-28.27M-23.58M-21.77M
EBIT (Quarter)
-22.90M-27.11M-24.60M-28.21M-29.64M-31.95M-37.40M-42.09M-47.33M-47.69M-47.04M-52.39M-60.64M-62.01M-53.32M-58.94M-45.59M-28.27M-23.58M-21.77M
Non-operating items
Interest & Investment Income (Quarter)
0.07M0.07M0.07M0.11M0.27M1.63M2.66M4.86M6.46M6.51M6.25M5.88M5.65M5.13M4.42M3.57M3.10M2.78M1.96M1.73M
Other Non Operating Income (Quarter)
Non Operating Income (Quarter)
Net income details
EBT (Quarter)
-22.83M-27.05M-24.53M-28.10M-29.55M-30.61M-35.06M-37.55M-41.19M-41.49M-41.11M-46.95M-55.85M-57.76M-49.73M-56.17M-43.30M-26.30M-21.75M-20.04M
Profit After Tax (Quarter)
-22.83M-27.05M-24.53M-28.10M-29.55M-30.61M-35.06M-37.55M-41.19M-41.49M-41.11M-46.95M-55.85M-57.76M-49.73M-56.17M-43.30M-26.30M-23.58M-20.04M
Income from Continuing Operations (Quarter)
-22.83M-27.05M-24.53M-28.10M-29.55M-30.61M-35.06M-37.55M-41.19M-41.49M-41.11M-46.95M-55.85M-57.76M-49.73M-56.17M-43.30M-26.30M-21.75M-20.04M
Consolidated Net Income (Quarter)
-22.83M-27.05M-24.53M-28.10M-29.55M-30.61M-35.06M-37.55M-41.19M-41.49M-41.11M-46.95M-55.85M-57.76M-49.73M-56.17M-43.30M-26.30M-21.75M-20.04M
Income towards Parent Company (Quarter)
-22.83M-27.05M-24.53M-28.10M-29.55M-30.61M-35.06M-37.55M-41.19M-41.49M-41.11M-46.95M-55.85M-57.76M-49.73M-56.17M-43.30M-26.30M-21.75M-20.04M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-22.83M-27.05M-24.53M-28.10M-29.55M-30.61M-35.06M-37.55M-41.19M-41.49M-41.11M-46.95M-55.85M-57.76M-49.73M-56.17M-43.30M-26.30M-21.75M-20.04M
Additional items
EPS (Basic) (Quarter)
-0.64-0.75-0.68-0.78-0.82-0.65-0.72-0.67-0.70-0.70-0.69-0.78-0.92-0.95-0.81-0.92-0.71-0.43-0.38-0.32
EPS (Weighted Average and Diluted) (Quarter)
-0.64-0.75-0.68-0.78-0.82-0.65-0.72-0.67-0.70-0.70-0.69-0.78-0.92-0.95-0.81-0.92-0.71-0.43-0.38-0.32
Shares Outstanding (Weighted Average) (Quarter)
35.73M35.79M35.85M36.12M36.14M46.80M42.02M56.06M57.62M58.32M58.72M60.18M60.28M60.73M60.54M61.22M61.39M61.41M61.37M61.80M
Shares Outstanding (Diluted Average) (Quarter)
35.73M35.91M35.85M36.12M36.14M46.80M42.02M56.06M59.17M58.32M58.72M60.18M60.38M60.43M60.54M61.22M61.30M61.34M61.37M61.80M
EBITDA (Quarter)
-22.84M-27.05M-24.69M-28.85M-29.86M-31.81M-34.56M-36.92M-42.10M-41.15M-38.86M-47.79M-55.98M-56.30M-50.26M-56.33M-43.46M-26.27M-23.63M-20.37M
Interest Expenses (Quarter)
0.17M0.30M0.32M0.31M0.32M0.32M0.32M0.45M0.87M0.88M0.83M0.80M0.81M0.81M0.14M
Shares Outstanding (Quarter)
35.85M35.98M36.08M36.16M36.18M48.75M48.94M58.98M59.22M59.89M59.92M60.32M60.43M60.85M60.86M61.39M61.39M61.45M61.45M61.91M